Novavax Tumbled Nearly 30% in Premarket Trading After Halving Sales Forecast on Low Vaccine Demand and Supply Glut

27
Comment
Favorite

Novavax Tumbled Nearly 30% in Premarket Trading After Halving Sales Forecast on Low Vaccine Demand and Supply Glut

Tiger Newspress2022-08-09

Novavax tumbled nearly 30% in premarket trading after halving sales forecast on low vaccine demand and supply glut.

Novavax said it now expects 2022 total revenue in the range of $2 billion to $2.3 billion, compared with its prior forecast of $4 billion to $5 billion.

The dismal outlook is the latest setback for Novavax that has also faced manufacturing hurdles and regulatory delays amid competition with market leaders Pfizer and Moderna.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Liuliusg
·2022-08-09
Ok
Reply
1
Report
Dawang
·2022-08-09
Who else cab we sell the vaccines to? 😂🤣😅
Reply
1
Report
KeN3
·2022-08-09
Can really put aside the shares on hand
Reply
1
Report
Home22
·2022-08-09
🤦🏻‍♂️😱
Reply
1
Report
lololol13
·2022-08-09
Ok
Reply
2
Report
lololol13
·2022-08-09
Ok
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1168244489?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-08-09 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168244489","market":"us","top_or_hot":-1,"title":"Novavax Tumbled Nearly 30% in Premarket Trading After Halving Sales Forecast on Low Vaccine Demand and Supply Glut","media":"Tiger Newspress","content":"<html><head></head><body><p>Novavax tumbled nearly 30% in premarket trading after halving sales forecast on low vaccine demand and supply glut.<img src=\"https://static.tigerbbs.com/0604dc9c980989058742461df8c1af57\" tg-width=\"671\" tg-height=\"544\" width=\"100%\" height=\"auto\"/></p><p>Novavax said it now expects 2022 total revenue in the range of $2 billion to $2.3 billion, compared with its prior forecast of $4 billion to $5 billion.</p><p>The dismal outlook is the latest setback for Novavax that has also faced manufacturing hurdles and regulatory delays amid competition with market leaders Pfizer and Moderna.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Tumbled Nearly 30% in Premarket Trading After Halving Sales Forecast on Low Vaccine Demand and Supply Glut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Tumbled Nearly 30% in Premarket Trading After Halving Sales Forecast on Low Vaccine Demand and Supply Glut\n</h2>\n\n<h4 class=\"meta\">\n\n2022-08-09 16:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax tumbled nearly 30% in premarket trading after halving sales forecast on low vaccine demand and supply glut.Novavax said it now expects 2022 total revenue in the range of $2 billion to $2.3 ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1168244489","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168244489","pubTimestamp":1660032990,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Novavax tumbled nearly 30% in premarket trading after halving sales forecast on low vaccine demand a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"Novavax在上市前交易中暴跌近30%，此前因疫苗需求低和供应过剩而将销售预测减半","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax tumbled nearly 30% in premarket trading after halving sales forecast on low vaccine demand and supply glut.Novavax said it now expects 2022 total revenue in the range of $2 billion to $2.3 billion, compared with its prior forecast of $4 billion to $5 billion.The dismal outlook is the latest setback for Novavax that has also faced manufacturing hurdles and regulatory delays amid competition with market leaders Pfizer and Moderna.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":9904667923,"gmtCreate":1660037752065,"gmtModify":1703477229734,"author":{"id":"3571112889855060","authorId":"3571112889855060","name":"Liuliusg","avatar":"https://static.tigerbbs.com/86e7691637ffe866f31f181dbe2ede72","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9904667923","repostId":1168244489,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9904682426,"gmtCreate":1660035160968,"gmtModify":1703477209691,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0},"htmlText":"Who else cab we sell the vaccines to? 😂🤣😅","listText":"Who else cab we sell the vaccines to? 😂🤣😅","text":"Who else cab we sell the vaccines to? 😂🤣😅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9904682426","repostId":1168244489,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9904688821,"gmtCreate":1660034429467,"gmtModify":1703477205793,"author":{"id":"4090570965971460","authorId":"4090570965971460","name":"KeN3","avatar":"https://static.tigerbbs.com/ffc770a2d3626a3e029ba2c461aac13d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Can really put aside the shares on hand","listText":"Can really put aside the shares on hand","text":"Can really put aside the shares on hand","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9904688821","repostId":1168244489,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9904688175,"gmtCreate":1660034418200,"gmtModify":1703477205619,"author":{"id":"4103282816795650","authorId":"4103282816795650","name":"Home22","avatar":"https://community-static.tradeup.com/news/3e5e55b062ffe0c519cbef858d125a27","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"🤦🏻‍♂️😱","listText":"🤦🏻‍♂️😱","text":"🤦🏻‍♂️😱","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9904688175","repostId":1168244489,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9904689281,"gmtCreate":1660033878345,"gmtModify":1703477201172,"author":{"id":"3583916713249739","authorId":"3583916713249739","name":"lololol13","avatar":"https://community-static.tradeup.com/news/7f37b3b51c631ccbedbe01fdda7adf7d","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9904689281","repostId":1168244489,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9904689617,"gmtCreate":1660033868444,"gmtModify":1703477201009,"author":{"id":"3583916713249739","authorId":"3583916713249739","name":"lololol13","avatar":"https://community-static.tradeup.com/news/7f37b3b51c631ccbedbe01fdda7adf7d","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9904689617","repostId":1168244489,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":27,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}